WUPPERTAL, Germany--(BUSINESS WIRE)--AiCuris Anti-infective Cures AG announced today the appointment of Cynthia Wat, MD as Chief Medical Officer, effective July 1, 2024. Dr. Wat is a highly accomplished pharmaceutical physician with over 25 years of experience in delivering novel treatments to patients with infectious diseases.

德国WUPPERTAL——（商业新闻短讯）——爱库里斯抗感染治疗公司今天宣布任命医学博士辛西娅·沃特为首席医疗官，自2024年7月1日起生效。Wat博士是一位成就卓著的药剂师，在为传染病患者提供新型治疗方面拥有超过25年的经验。

Her proven track record of designing and executing successful clinical development strategies from early to late-stage development and through market licensure, will benefit the company as it prepares to advance its Phase 3 product candidate pritelivir towards market authorization. Pritelivir is AiCuris’ innovative therapeutic candidate inhibiting HSV replication which is currently being evaluated in a pivotal Phase 3 clinical trial for the treatment of acyclovir-resistant HSV infections in immunocompromised patients.

她在设计和执行从早期到晚期开发以及通过市场许可的成功临床开发战略方面的良好记录，将使公司受益，因为它准备将其第三阶段候选产品pritelivir推向市场授权。Pritelivir是AiCuris抑制HSV复制的创新治疗候选药物，目前正在一项关键的3期临床试验中进行评估，用于治疗免疫功能低下患者的阿昔洛韦耐药HSV感染。

As part of her role, Dr. Wat will be responsible for the management and global development of AiCuris' clinical pipeline of innovative therapeutic candidates aiming to improve the lives of immune compromised patients..

作为其职责的一部分，Wat博士将负责管理和全球开发AiCuris创新治疗候选药物的临床管道，旨在改善免疫缺陷患者的生活。。

AiCuris also provided an update on further leadership team changes. Holger Zimmermann, PhD, has stepped down from his position as Chief Research and Development Officer to pursue other opportunities. Dr. Zimmermann was part of the spin-out in 2006 which became AiCuris, served as AiCuris CEO from 2015 to April 2023 and was key contributor in the discovery and development of letermovir which was out-licensed to MSD in 2012 and is currently marketed as PREVYMIS®..

爱库里斯还提供了有关领导团队进一步变化的最新信息。霍尔格·齐默尔曼博士已经辞去首席研发官的职位，寻求其他机会。Zimmermann博士是2006年螺旋输出（spin out）的一部分，后来成为爱库里斯（AiCuris），于2015年至2023年4月担任爱库里斯（AiCuris）首席执行官，是莱特莫韦（letermovir）发现和开发的关键贡献者。莱特莫韦于2012年获得MSD许可，目前以PREVYMIS®销售。。

“As we complete patient enrollment in our pivotal Phase 3 study with pritelivir in the first half of 2025, Cynthia’s extensive experience in product filing and negotiating with global health authorities will be vital to rapidly and successfully position our lead candidate for commercialization,” said Larry Edwards, CEO of AiCuris.

AiCuris首席执行官拉里·爱德华兹（LarryEdwards）表示：“随着我们在2025年上半年完成与普瑞特利韦（pritelivir）的关键性3期研究的患者登记，辛西娅在产品备案和与全球卫生当局谈判方面的丰富经验将对我们快速成功地定位商业化的主要候选人至关重要。”。

“I am looking forward to working with Cynthia as we continue to execute on our mission of providing multiple therapeutic solutions for immunocompromised patients in a more efficient and effective manner. On behalf of the AiCuris team, I also would like to sincerely thank Holger for his invaluable support since the inception of the company and his contributions over the years.

“我期待着与辛西娅合作，我们将继续以更高效和有效的方式为免疫功能低下的患者提供多种治疗方案。我还代表爱库里斯团队衷心感谢霍尔格自公司成立以来提供的宝贵支持以及他多年来的贡献。

We wish him all the best for his future endeavors.”.

我们祝他今后一切顺利。”。

“Joining AiCuris presents a unique opportunity to rapidly and effectively deliver innovative therapies to immunocompromised individuals. The company is one of the few private biotech companies that successfully developed a commercial-stage drug that is improving the lives of thousands of seriously ill patients.

“加入AiCuris提供了一个独特的机会，可以快速有效地为免疫功能低下的个体提供创新疗法。该公司是少数成功开发出商业阶段药物的私营生物技术公司之一，该药物正在改善数千名重症患者的生活。

Its differentiated pipeline candidates hold the potential to deliver substantial value and life-saving treatments to vulnerable patient populations where simple infections can pose serious threats. I am eager to contribute to these efforts together with the AiCuris team and to expedite the path toward product approval, ensuring that critical medical needs are met and that vulnerable patients receive the care they urgently require,” added Cynthia Wat, MD..

其差异化的候选管道有可能为简单感染可能构成严重威胁的弱势患者群体提供实质性价值和挽救生命的治疗。我渴望与AiCuris团队一起为这些努力做出贡献，并加快产品批准的步伐，确保满足关键的医疗需求，并确保弱势患者获得他们迫切需要的护理，”医学博士辛西娅·沃特补充道。。

Cynthia Wat joins AiCuris from her most recent position as a Pharmaceutical Consultant and Director at ID Pharma Consultancy Ltd. With more than 25 years of extensive global drug development experience, she has held leadership and managerial roles for licensed products Fuzeon®, Pegasys®, and Tamiflu® at Roche that included pivotal registration trials and multiple filing activities.

辛西娅·沃特（CynthiaWat）最近加入爱库里斯（AiCuris），担任ID Pharma Consultancy Ltd.的药物顾问和董事。凭借25年以上丰富的全球药物开发经验，她在罗氏（Roche）担任许可产品Fuzeon®、Pegasys®和Tamiflu®的领导和管理职务，其中包括关键的注册试验和多项备案活动。

As a recognized expert in infectious diseases and hepatitis, Dr. Wat has a proven track record for creating and successfully implementing novel clinical trial designs and clinical development strategies for chronic Hepatitis B, COVID-19, and other respiratory viruses and is experienced in a broad range of modalities, small molecules, biologics, RNA therapeutics including antisense oligonucleotides and predictive biomarker research.

作为传染病和肝炎领域公认的专家，Wat博士在创建和成功实施针对慢性乙型肝炎，新型冠状病毒和其他呼吸道病毒的新型临床试验设计和临床开发策略方面拥有良好的记录，并且在广泛的模式，小分子，生物制剂，RNA治疗剂（包括反义寡核苷酸）和预测性生物标志物研究方面经验丰富。

Additionally, she is a strong collaborator with health authorities, and has provided recommendations to NICE and other regulators in her role at the Faculty of Pharmaceutical Medicine. Dr. Wat holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) from St. Mary's Hospital Medical School, Imperial College, London, a Diploma in Pharmaceutical Medicine from the Faculty of Pharmaceutical Medicine (FPM) and is a Member of the Royal College of Physicians (MRCP)..

此外，她是卫生部门的有力合作者，并在药物医学院为NICE和其他监管机构提供了建议。Wat博士拥有伦敦帝国理工学院圣玛丽医院医学院的医学学士、外科学士学位（MBBS），以及药学学院（FPM）的药学文凭，并且是皇家医师学院（MRCP）的成员。。

About AiCuris

关于爱库里斯

AiCuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS®, marketed by our partner MSD, prevents CMV in a defined group of transplant recipients. Our pivotal Phase 3 candidate pritelivir aims to address recurrent and resistant HSV infections in a broad population of patients with weakened immune systems.

艾库里斯正在满足日益增长的免疫功能低下人群的需求，这些人群需要精确的疗法来有效治疗感染。我们的旗舰产品PREVYMIS®由我们的合作伙伴MSD销售，可预防特定移植受者群体中的CMV。我们关键的3期候选药物普利韦旨在解决免疫系统减弱的广大患者中复发性和耐药性HSV感染的问题。

For immunocompromised people, an otherwise manageable infection can mean life or death. AiCuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future..

对于免疫功能低下的人来说，原本可以控制的感染可能意味着生命或死亡。爱库里斯凭借其专业知识和不断增长的渠道，致力于现在和未来为他们提供治疗解决方案。。